Basilea Pharmaceutica AG Allschwil banner
B

Basilea Pharmaceutica AG Allschwil
SWB:PK5

Watchlist Manager
Basilea Pharmaceutica AG Allschwil
SWB:PK5
Watchlist
Price: 62.6 EUR 1.62%
Market Cap: €755.7m

Wall Street
Price Targets

PK5 Price Targets Summary
Basilea Pharmaceutica AG Allschwil

There are no price targets for PK5.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Basilea Pharmaceutica AG Allschwil Competitors:
Price Targets
CDNA
CareDx Inc
27% Upside
PTCT
PTC Therapeutics Inc
20% Upside
INO
Inovio Pharmaceuticals Inc
423% Upside
ZEAL
Zealand Pharma A/S
80% Upside
NYXH
Nyxoah SA
148% Upside

Revenue
Forecast

9% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
9% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG Allschwil's revenue is 9%. The projected CAGR for the next 4 years is 3%.

Operating Income
Forecast

N/A
Past Growth
-33% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss
N/A
Past Growth
-33% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's operating income for the next 4 years is -33%.

Net Income
Forecast

N/A
Past Growth
-36% / Year
Estimated Growth
Estimates Accuracy
-38%
Average Miss
N/A
Past Growth
-36% / Year
Estimated Growth
Estimates Accuracy
-38%
Average Miss

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's net income for the next 4 years is -36%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PK5's stock price target?
Not Available

PK5 doesn't have any price targets made by Wall Street professionals.

What is Basilea Pharmaceutica AG Allschwil's Revenue forecast?
Projected CAGR
3%

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG Allschwil's revenue is 9%. The projected CAGR for the next 4 years is 3%.

What is Basilea Pharmaceutica AG Allschwil's Operating Income forecast?
Projected CAGR
-33%

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's operating income for the next 4 years is -33%.

What is Basilea Pharmaceutica AG Allschwil's Net Income forecast?
Projected CAGR
-36%

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's net income for the next 4 years is -36%.

Back to Top